Novartis Ag (NVS) EBT (2009 - 2026)

Novartis Ag has disclosed EBT across 18 years of filings, most recently posting $4.3 billion for Q2 2026.

• In Q2 2026, EBT fell 5.78% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $21.2 billion (down 6.33% YoY), while the FY2025 annual figure was $16.4 billion, up 19.88% from the prior year.
• EBT came in at $4.3 billion for Q2 2026 at Novartis Ag, up from $3.8 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $10.4 billion in Q4 2024 to a low of $1.6 billion in Q3 2023.
• Average EBT over 5 years is $4.2 billion, with a median of $3.8 billion recorded in 2024.
• Year-over-year, EBT plunged 66.92% in 2022 and jumped 118.11% in 2024.
• Over 5 years, EBT stood at $5.6 billion in 2022, then grew by 20.29% to $6.7 billion in 2023, then jumped by 53.5% to $10.4 billion in 2024, then fell by 13.68% to $8.9 billion in 2025, then tumbled by 52.24% to $4.3 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were $4.3 billion in Q2 2026, $3.8 billion in Q1 2026, and $8.9 billion in Q4 2025.